T +44 1279 645645 E argenta@glpg.com
A truly integrated approach to small molecule drug discovery from hit identification to pre-clinical candidate. Find out more >
A wealth of experience in all aspects of drug discovery chemistry with a proven track record. Find out more >
Accelerate hit-finding with high-throughput docking combined with pharmacophore and similarity searching. Find out more >
Comprehensive biology capabilities with expertise ranging from molecular biology to biomarker identification. Find out more >
A cascade of approaches ranging from early in vitro assessment to in vivo pharmacokinetics. Find out more >
Understanding and de-risking molecules as future pharmaceuticals. Find out more >
Expert mechanistic and predictive insight into human respiratory diseases. Find out more >
Integrated de-risking of drug candidates to identify your most robust molecules. Find out more >
Argenta is a trusted strategic partner with significant industry experience in providing contract small molecule drug discovery services. Argenta offers a truly integrated approach to undertaking complete drug discovery programmes as well as hit identification, hit-to-lead, and lead optimisation projects. Our industry-seasoned, multi-disciplinary research teams work closely with our clients' scientists to enhance knowledge, add manpower, shorten time to development candidate identification, and increase the value of their drug discovery programmes.
Mechelen, Belgium - Galapagos NV (Euronext: GLPG) announces the acquisition of Argenta Discovery 2009 Ltd., a privately held contract research drug discovery company with 140 employees. Read full article »
18-22 September 2010 Representing Argenta: Jeremy Billson, John Montana, Vince Russell All events »